Board of Directors
Exacis is building a Scientific Advisory Board that combines immunology, oncology, and mRNA / gene editing scientific expertise. Each member will be an innovator and a science focused practitioner.
Mark Corrigan MD
Dr. Corrigan is a leader in life sciences. Following his academic training in psychiatry and appointment at UNC, Dr. Corrigan spent a decade at Pharmacia rising to positions of increasing responsibility ultimately as Group VP for Clinical Research and Experimental Medicine. He then joined Sepracor, a mid-size specialty pharmaceutical company in the C suite and leading R&D. Following a successful exit, Dr. Corrigan took his first CEO position at Zalicus leading the company through a merger. Subsequent to that effort Dr. Corrigan co-Founded a rare diseases company, Tremeau Pharmaceuticals and following its acquisition, he assumed the leadership of Correvio Pharma, a publicly traded, global commercial stage company.
Dr. Corrigan has extensive Board experience in research, clinical and commercial stage companies where he has served as Executive Chairman, Chairman, and on all committees. He has led strategic turnarounds and mergers and is unabashedly driven by a passion to create new medicines and bring them successfully to market. He is known for his collaborative and inclusive work style and for bringing together diverse skill sets for the benefit of the enterprises he is involved in.
Mark Corrigan MD
Chair of Exacis Board of Directors
Gregory Fiore MD
- Dr. Fiore is a co-founder and is the President and Chief Executive Officer of Exacis. He is a pharmaceutical/biotechnology executive and entrepreneur and is a co-founder and former CEO of Sollis Therapeutics, where during his tenure as CEO he raised ~$50M in funding from State grants as well as strategic venture investors. He oversaw the regulatory strategy development and initiation of pivotal clinical trials for the Company’s lead compound.
- Before this he provided C-level medical support as consultant and acting Chief Medical Officer for several early stage biotechnology companies through a consultancy he founded in 2014. Prior to that he was the first CMO of The Medicines Company (MDCO) and held a variety of leadership roles at MDCO, Merck and Abbott Laboratories after spending time as a management consultant at McKinsey and Company.
- Dr. Fiore completed Internal Medicine internship and residency as well as received clinical Pulmonary / Critical Care training at Harvard Medical School following his graduation as class valedictorian with his MD degree from New York Medical College.
- Dr. Fiore serves on several Medical and Business Advisory Committees / Boards. He is on the Executive Board of the Institute of Neuromodulation (ION), the Scientific Advisory Board for Advera Health Analytics, the Business Advisory Board for the Advanced Group of Companies, and the Editorial Advisory Board of the journal Clinical Leader. He serves as an advisor to Fiore Healthcare Advisors and SSI Strategy as well as several biotechnology companies and previously served on the Board of Dubset Media Holdings and the Executive Committee for the Safety of Oral Anticoagulants (SOAR) Registry.
Gregory Fiore MD
Co-Founder, President and CEO
Scientific Advisory Board
Exacis is building a Scientific Advisory Board that combines immunology, oncology, and mRNA / gene editing scientific expertise. Each member will be an innovator and a science focused practitioner.
Matt Angel PhD
- Dr. Angel is a pioneer in the field of mRNA therapeutics, and a prolific inventor, holding more than 80 patents covering mRNA, nucleic-acid delivery, gene-editing, and cell-reprogramming technologies.
- Dr. Angel serves as President and is a co-founder of Factor Bioscience, a cell engineering technology development company in Cambridge, Massachusetts. Prior to co-founding Factor Bioscience, he was a member of MIT Lincoln Laboratory’s Biodefense Systems Group, where he developed technologies for the detection and mitigation of biological weapons threats.
- Dr. Angel received his B.S. in engineering from Princeton University, and his PhD in electrical engineering from the Massachusetts Institute of Technology, where he studied the innate immune system and its response to exogenous mRNA.
- In addition to serving as its CSO, he serves on the Board of Directors of Exacis.
Matthew Angel PhD
Scientific Advisory Board Chair
Pamela Munster MD
Professor, Department of Medicine (Hematology/Oncology), UCSF
Dr. Munster received her medical degree from the University of Bern, Switzerland; completed her residency in Internal Medicine at Indiana University Medical Center, then moved to Memorial Sloan-Kettering Cancer Center, New York for her oncology and hematology fellowship.
She served at Memorial Sloan Kettering as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute, Tampa, Florida.
Currently, Dr. Munster is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Experimental Therapeutics. She is also Co-Director of the Center for BRCA Research, a BRCA-focused clinical and research program at the Helen Diller Family Comprehensive Cancer Center at UCSF.
Pamela Munster MD
Scientific Advisory Board Member
Dr. Gunnar Kaufmann
Dr. Kaufmann is an immunologist and cell therapy expert with extensive experience in discovery and preclinical development of both biotherapeutics and small molecule drug product candidates. He is currently the Chief Scientific Officer at Oncternal Therapeutics, Inc, a NASDAQ-traded clinical-stage immuno-oncology company. Prior to joining Oncternal, he served as Senior Vice President, Immunotherapy, Head of Research and Global Partnerships at Sorrento Therapeutics, Inc. Dr. Kaufmann was previously a faculty member at The Scripps Research Institute and still serves as Adjunct Assistant Professor in the Departments of Chemistry and Immunology and Microbial Science. Dr. Kaufmann holds a B.S. in human biology from Phillips University Marburg, an M.S. in human biology from Ernst-Moritz-Arndt University Greifswald, and a Ph.D. from The Scripps Research Institute’s Biology Program.
Gunnar Kaufmann PhD
Scientific Advisory Board Member
Christopher Rohde PhD
Dr. Rohde has extensive experience developing mRNA technologies and technologies for high-throughput and high-content screening. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many others. Dr. Rohde is currently leading Factor’s efforts to apply our RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries, for the study and treatment of Alzheimer’s disease.
Christopher Rohde PhD
Scientific Advisory Board Member
Caron Jacobson
Caron Jacobson is an Assistant Professor of Medicine at Harvard Medical School and a physician in the lymphoma group at Dana-Farber Cancer Institute. She is a clinical and translational researcher with an interest in immunologic, and more specifically cellular immune, therapies for the treatment of lymphoma and other cancers. Dr. Jacobson has to be the Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber, which houses and oversees our commercial CAR T-cell efforts as well as our research program of engineered and other cellular therapies for the treatment of both hematologic and solid tumor malignancies.
Caron Jacobson MD MMSc
Scientific Advisory Board Member
Eric Westin MD
Dr. Westin is a member of the Exacis Scientific and Medical Advisory Board. He received his BS in Biology and MD from the combined degree program at Rensselaer Polytechnic Institute and Albany Medical College followed by training in Internal Medicine at the University of Pittsburgh and fellowship in Oncology at the National Cancer Institute. Following an academic career at Virginia Commonwealth University, West Virginia University, and the National Institute on Aging he joined the early phase oncology group at Lilly in 2006 and subsequently joined Millennium/Takeda in 2011.
Dr. Westin lead the antimitotic group and was promoted to Vice President & Head of Early Clinical Research and Development in the Oncology Therapeutic Area Unit. As the lead for that group he worked closely with both research and business development to help refine strategy for the shift in portfolio biology toward targeted therapy and immuno-oncology. In 2017, Dr. Westin joined ImmunoGen and is currently Vice President of Clinical Development and Translational Sciences.
Eric Westin MD
Scientific Advisory Board Member
Evren Alici MD PhD
Dr. Evren Alici is a senior researcher and group leader in Hematology at Karolinska Institutet (KI), Department of Medicine in Stockholm, Sweden where he leads a group of more than 20 scientists. He also serves as co-director of KI’s NextGenNK, an international competence center for the development of next-generation NK cell-based cancer immunotherapies. He received his M.D. and residency training at the Ege University, Turkey followed by a Ph.D. at KI.
He is a member of several international and national committees and advisory boards and is the Chairman and CEO of Vycellix. Dr. Alici participated in the planning and design of the first clinical study with gene-modified cells in Sweden and authored the final publication. He was also responsible for the first autologous NK cell clinical trial that was classified as advanced therapy medicinal product use.
Evren Alici MD PhD
Scientific Advisory Board Member
The Future of Cell Therapies
Exacis is developing advanced cellular therapeutics with the aim to deliver potent, targeted, effective cell therapies to harness the human immune system and cure cancer. This is the future.